XTX Topco Ltd Sells 283,725 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)

XTX Topco Ltd reduced its stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) by 81.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 63,530 shares of the company’s stock after selling 283,725 shares during the quarter. XTX Topco Ltd owned about 0.05% of Mersana Therapeutics worth $91,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new stake in shares of Mersana Therapeutics in the 4th quarter worth approximately $37,000. Avanza Fonder AB bought a new stake in shares of Mersana Therapeutics in the 4th quarter worth approximately $81,000. Wells Fargo & Company MN boosted its position in shares of Mersana Therapeutics by 40.3% in the 4th quarter. Wells Fargo & Company MN now owns 67,483 shares of the company’s stock worth $97,000 after purchasing an additional 19,368 shares in the last quarter. Sei Investments Co. bought a new position in Mersana Therapeutics in the 4th quarter valued at approximately $99,000. Finally, SG Americas Securities LLC boosted its stake in Mersana Therapeutics by 28.7% during the 4th quarter. SG Americas Securities LLC now owns 112,291 shares of the company’s stock valued at $161,000 after purchasing an additional 25,058 shares during the last quarter. 93.92% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on MRSN. William Blair began coverage on Mersana Therapeutics in a research note on Thursday, February 6th. They set an “outperform” rating on the stock. Wedbush reiterated an “outperform” rating and set a $4.00 target price on shares of Mersana Therapeutics in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $4.00.

Mersana Therapeutics Price Performance

NASDAQ MRSN opened at $0.37 on Wednesday. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. Mersana Therapeutics, Inc. has a 1-year low of $0.26 and a 1-year high of $3.63. The stock has a market capitalization of $46.04 million, a price-to-earnings ratio of -0.61 and a beta of 1.68. The business’s fifty day moving average price is $0.41 and its 200-day moving average price is $1.16.

Mersana Therapeutics (NASDAQ:MRSN) last announced its earnings results on Monday, March 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.05. The business had revenue of $16.36 million for the quarter, compared to analysts’ expectations of $7.71 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. On average, equities analysts predict that Mersana Therapeutics, Inc. will post -0.62 earnings per share for the current year.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.